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Papillary thyroid carcinoma is the most common thyroid malignancy, and has an excellent prognosis, even with cervical lymph
node metastasis; however, histological variants are considered relevant, which may be associated with familial adenomatous
polyposis and tumor aggressiveness. Histological features, such as vascular and/or lymphatic invasion, angiogenesis, multifocality,
high cellular proliferation rate, neoplastic cell dissemination, and the histological varieties, are indicative of poor prognosis,
together with associated clinical factors: age, sex, and tumor size.
1.Introduction
Papillary thyroid carcinoma (PTC) represents 1% of all
malignancies [1] and represents 70–80% of all thyroid can-
cers. Several factors, are associated with the development of
this neoplasm, including genetic alterations, growth factors
and radiation [2]. The prognosis of this tumor is strongly
associated with various clinical variables as follows: age,
tumorsize,andhistologicalparameterssuchasextracapsular
extension, extrathyroidal extension, lymph node invasion,
distant metastasis and histological variants.
Clinicalandhistologicalfeaturesareusedtoclassifythese
carcinomas in diﬀerent clinical stages, which inﬂuences the
treatment plan and prognosis for survival of patients with
PTC. RET/PTC is an important oncogene in the initiation
events in the pathogenesis of cancers and is rearranged,
particularly in patients who have been exposed to radiation.
The activation of the BRAF gene accounts for approximately
45% of sporadic mutations that result from increased BRAF
kinase activity. Approximately 80% of all mutations have
transversion events, that is, the transversion from thymine
to adenine at nucleotide 1799 [3].
The purpose of this study was to conduct a review of
various publications with respect to tumor biology, risk
factors associated with the development of PTC, histological
and clinical features, and treatment of PTC.
2. Review of the ClinicalFeatures and
Metastasisof PapillaryThyroid Carcinoma
Diﬀerent systems of classiﬁcation (AMES, AGES, MACIS,
EORTC)wereusedtopredicttherisksofPTC.Thesesystems
classify diﬀerent features such as the following: age, gender,
size, extension, and distant metastases. TNM classiﬁcation
evaluates the prognosis of the disease associated with nodal
status [4]. TNM is a system that accurately predicts life
expectancy [5]. Most metastases are often found in lymph
nodes, may aﬀect the clinical course of the injury, may be
indicative of distant metastases, and have signiﬁcant eﬀects
on the course of the disease [6]. Lymphatic metastasis may2 ISRN Oncology
be associated with features such as multifocality, patient
age, local recurrence, and distant metastases regardless of
tumor size and extrathyroidal extension, especially those
occurring in the central region of the neck [4, 7, 8]. Studies
by Wada et al. [6] have indicated that the presence of lymph
node metastases occur more frequently and are associated
with a higher risk of recurrence in younger patients (<45)
than in older (≥45) patients. However, recurrences of PTC
are more frequent in older patients than younger patients,
independent of metastasis. Therefore, the increase in the
number of lymph node metastases may increase the risk for
a worse prognosis. Results of clinical studies indicate that
older patients who have lymph node metastases have a worse
prognosis than younger patients. Lymphatic metastasis at
the cervical level does not seem to aﬀect patient survival,
although the risk of local or regional recurrence is increased
[9]. Ultrasonography is a method of choice for the detection
and diagnosis of cervical lymph node metastases in patients
with PTC. Ultrasonography is used preoperatively and
displays a sensitivity of 51–62% and a speciﬁcity of 79–
98% [10]. Detection of occult metastases can be treated
with prophylactic radioiodine to avoid radical procedures.
However, treatment of evident nodal disease necessitates
radicallymphadenectomy.DistantmetastasisofPTCarerare
andusuallyoccurinadvancedstagesofthedisease,especially
in lung, bone, lymph nodes of the chest, pancreas, and breast
[11]. Some variants of PTC are associated with poor progno-
sis and are characterized by tall cells as well as columnar and
insular patterns [12]. The management of PTC is variable
and depends on the characteristics of each tumor; many
cases have been subjected to extensive surgery, radioactive
iodine ablation or external beam radiotherapy. Radioactive
adjuvant therapy (RAI) is used to treat diﬀerentiated thyroid
disease, eradicate microscopic diseases, and detect early
recurrences due to increased measurement sensitivity of this
material [5]. In PTC patients, the eﬀectiveness of RAI to
decrease the risk of relapse of the disease is reduced by
up to 54%. However, RAI may prolong the life expectancy
in apparently disease-free patients following surgery [5].
Age is considered a major risk factor, as it has been
shown that patients over 45 years displayed an increased
risk of death by 5.4- to 6.05-fold [5, 13]. Therefore, total
thyroidectomy favors increased life expectancy compared
to lobectomy. Several authors mention that treatment with
total thyroidectomy is associated with several complications.
However, repeated surgeries following total thyroidectomy
were reported in less than 5% [14]( Figure 1).
3. Review of Variants of Papillary
Thyroid Carcinoma.
Many morphological variants of PTC have been described,
and their diﬀerent behaviors have been characterized [15].
4. DiffuseSclerosingVariant(DSVPC)
DSVPC is a rare variant of papillary thyroid carcinoma
detected in 1.8% of PTC cases evaluated in large studies.
DSVPC is commonly seen in young, this neoplasm ranging
from 19.5 to 34.7, years and has a higher incidence of
cervical lymph node metastases [16, 17]. Several authors
have suggested that the prognosis may be unfavorable and,
therefore, requires aggressive treatment [18]. The clinical
features may include palpable thyroid nodules associated
with unilateral and ipsilateral or bilateral cervical metastases.
Themultifocality,bilateralityandextra-thyroidextensionare
observed more frequently in this carcinoma compared with
the conventional variant. [19]. Ultrasonographic studies of
this variant, are frequently observed, dispersed calciﬁcation
in both lobes and diﬀuse and hypoechoic nodules that are
diﬀuse and ill deﬁned. In addition, these studies indicate that
most tumors grow to approximately one centimeter in diam-
eter. Radiography detects microcalciﬁcations that may not
be visible on ultrasounds and may be related to psammoma
bodies. Therefore, these radiological features may predict
the potential extent of thyroid cancer. Histology is used to
characterize dense ﬁbrosis, extensive squamous metaplasia,
lymphoid inﬁltration in the presence of germinal centers,
and psammoma body formation with areas of conventional
PTC [16]( Figure 2). Immunohistochemical studies are used
to evaluate thyroglobulin, TTF-1, HBME1, and galectin-3
in PTC [20]. The aggressiveness of this type of PTC may
be associated with extrathyroidal extension, cervical lymph
node metastasis, and distant metastasis associated with
advanced clinical stages. [21]. However, these characteristics
have been controlled to improve prognosis using aggressive
surgical treatment, RAI, and external radiotherapy, which
has worked to reduce locoregional relapse in patients with
locally advanced disease [22]. Falvo et al. [23] in a study of
83 patient with the diﬀuse sclerosing variant of PTC and
168 patients with classical PTC illustrated that the incidence
of laterocervical lymph node pathology at diagnosis was
signiﬁcantly higher for the diﬀuse sclerosing variant. Studies
made by Lam and Lo [17] concluded that complete resection
did not result in later recurrence in any of the patients;
therefore, cosmetic and complication-free surgery should be
considered. Additionally, the rates of recurrence and distant
metastases were increased compared with those for classical
PTC patients.
Conventional PTC rearrangements of RET/PTC are
associated with high prevalence rates in children and young
adults; the age of presentation is signiﬁcantly lower com-
pared to other types of PTC. Therefore, it is not surprising
that the presence of RET/PTC is associated with initial
genetic events such as the DSVPTC and that these tumors
are susceptible to RET therapy [24, 25].
5.TallCellVariant(TCVPC)
The TCVPC was ﬁrst described in 1976 by Hawk and Hazard
as an aggressive variant of PTC [26]. TCVPC is deﬁned as a
tall-cell papillary carcinoma containing cells that are at least
two times higher in height than width with nuclei that are
oriented to the basement membrane. To consider TCVPC,
there must be 30%–50% tall cells in the tumor [27]. The
TCVPC represent 3.8–10.4% of PTC, and histology indicates
that TCVPC is a poor prognostic factor when considered in
isolation [28]. Factors such as clinical stage, grade, and ageISRN Oncology 3
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Figure 1: (a) Total thyroidectomy in PTC with extracapsular invasion, (b) PTC classical/conventional [20x], (c) vascular invasion in PTC
classical/conventional (4x), and (d) nerve invasion in PTC [20x].
(a) (b)
Figure 2: (a) DSVPC. Tumour replaces the lobe of gland, accompanied by dense ﬁbrosis (20x), (b) squamous metaplasia [20x].
(over 50 years, range 34–72 years) are related to prognosis
[29]. A meta-analysis study conducted by Jalisi et al. [28]h a s
indicatedthattheprognosisforTCVPCispoorbecausethese
tumors represent high local recurrence, lymph node metas-
tasis, and mortality. These results suggest the necessity for
aggressive treatment with at least total thyroidectomy. The
ultrasoundresultsrevealmicrolobulatedhypoechoicnodules
with microcalciﬁcations that are associated with extrathy-
roidal extension and cervical lymph metastasis [29]. TCVPC
occupies at least 30–50% of the tumor. The cytoplasm of the
cells is abundant and eosinophilic. Oncocytic diﬀerentiation,
syncytial cell growth, and capsular and vascular invasion
are observed [27]( Figure 3). In addition, diﬀerentiation or
squamous metaplasia is caused by persistent thyroglossal
duct- or branchial pouch-derived structures. These features
of squamous cells lead to the transformation of squamous
cell carcinoma such as undiﬀerentiated squamous cell carci-
nomas, especially the spindle cell type [30], which indicate
poor prognosis and survival. The receptor tyrosine kinase
c-Met interacts with the hepatoctic growth factor (HGF).
Overexpression of c-Met induces cell motility and invasion.
In addition, c-Met overexpression promotes the aggressive4 ISRN Oncology
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Figure 3: (a) TCVPC typically appearance [20x]; (a,b) TCVPC shows characteristic cytologic features, including elongate cells, intracy-
toplasmic borders, and eosinophilic cytoplasm [20x].
and invasive behavior of cells in thyroid carcinoma [31–33].
In a study of the mitogenicity of RET/PTC3 by Basolo et al.
[34], the CTV RET/PTC3 oncogene was detected in 14 of
39 (35.8%) cases studied. This result may indicate a more
aggressiveoncogenicpotential,whichmayexplainthebehav-
ior of TCVPC and may suggest discarding the idea that the
aggressivenessofTCVPCiscorrelatedtotheclinicalfeatures.
The aggressive behavior of the tall cell variant may
also be related to the higher prevalence of activating point
mutations of BRAF in the tall cell variant than in classical
PTC [35]. Indeed, papillary cancers of any subtype that have
BRAF mutations have a higher frequency of extraglandular
extension and nodal metastases. The incidence of the tall cell
variant is accentuated by the fact that it is overrepresented
in thyroid carcinomas that are RAI found that 20% of ﬂu-
orodeoxyglucose positron-emission tomogram (FDGPET)
positive/RAI refractory [36].
6.SolidVariant(SVPC)
The SVPC should be considered when representing more
than 50% of the tumor mass because diﬀerent variants of
PTC may occur as focal solid patterns. This variant occurs
frequentlyinchildren,andover30%ofthereportedcasesare
associated with the Chernobyl nuclear accident [37]. Studies
that were conducted in Japan indicate that the SVPC is
aggressive and has a poor prognosis. However, these ﬁndings
h a v en o tb e e nc o n ﬁ r m e di nE u r o p ea n dN o r t hA m e r i c a .
These tumors should not be grouped with other tumors that
are more aggressive but should be characterized as poorly
diﬀerentiated carcinomas with insular patterns [38].
In a study made by Nikiforov et al. [39]i n2 0p r i m a r y
cases of SVPC, they found that this variant is associated with
a slightly higher frequency of distant metastases and less
favorable prognosis than classical PTC.
Silveretal.[20]recommendinaggressivevariantsofPTC
including the SVPC that The surgeon must be prepared to
perform a total thyroidectomy, central compartment neck
dissection, additional lymphadenectomy and/or resection
of invaded surrounding structures, and search for distant
metastasis.
7. PapillaryThyroid Microcarcinoma(PTMC)
PTMC is deﬁned as carcinoma of the thyroid gland and is
undetectable during the preoperative clinical examination.
Therefore, PTMC is diagnosed as a benign lesion. Removal
of the thyroid gland can reveal the presence of a tumor,
which is less than 10mm at its widest diameter [40]. The
PTMC can be indirectly detected because the diagnosis is
indicated by the presence of cervical lymph node metastases.
[37]. This type of carcinoma has also been given the name
of occult papillary carcinoma, which describes PTC foci
less than 1–1.5cm [41]. Aspiration biopsy that is guided by
ultrasound is relatively sensitive with 60–90% speciﬁcity, a
positive predictive value of 100%, a negative predictive value
of 80%, and a precision rate of up to 85% for the diagnosis
of thyroid cancer. PTMC can be diagnosed in lesions that are
greater than 3mm. Ultrasound-guided biopsy can be used
for patients with suspicious cervical lymph nodes [41]. If
PTMC appears benign, conservative surgery is the treatment
of choice. However, the patient should be kept under
surveillance because up to 11% of patients have metastases
[42].ThePMCvariantisthemostcommonformofPTCthat
is identiﬁed at autopsy and in nonthyroid pathologies. Once
detected and treated, most of these tumors do not metasta-
size, and in some studies, they have no eﬀects on mortality.
Previousstudieshavereportedmetastasistothelymphnodes
in 3–15% of cases with a mortality rate of 1% [43]. Studies
by Bologna-Molina et al. [44] on syndecan protein-1 (SDC-
1) demonstrated that noninvading PTMC cells expressed
lower levels of SDC-1 compared to extracapsular invading
PTMC cells. These results show that the overexpression of
SDC-1 in PTMC may be related to tumor progression. The
tumor progression may be associated with multifocality to
promote metastasis. A study by Dunki-Jacobs et al. [45]h a s
shown that multifocality is often associated with cervical
metastasis. A study by Hay et al. [13] found that, in 900
cases, 23% of PTMC was associated with the presence
of metastasis and that only one patient had evidence of
distant metastasis. The ﬁndings of this study are similar
to those by Dunki-Jacobs et al. [45], and Bologna-Molina
et al. [44] indicate that multifocality is a major factor for
tumor progression. PTMCs are generally well-diﬀerentiatedISRN Oncology 5
neoplasms, which show characteristic architecture as well as
cytological and immunohistochemical features. In addition,
the nuclei have a frosted glass appearance and have nuclear
grooves that invaginate into the cytoplasm. Other notable
features are the presence of desmoplasia and the proximity
of the tumor near the capsule [41]. Immunohistochemical
studies reveal the conventional pattern of PTC including the
injury-positive markers TTF-1 and thyroglobulin, Galectin-
3, and HBME-1. The arrangements of RET/PTC1, which
have been linked to aggressive biological behaviors, indicate
molecular changes that are observed in the early stages of
carcinogenesis but are not required for tumor progression
[41]. The PTMC may include BRAF mutations that are
associated with extrathyroidal extension and cervical lymph
node metastases. Therefore, BRAF mutations may be useful
to predict the recurrence of these neoplasms [46].
8.Columnar CellVariant(CCVPC)
The CCVPC is a rare subtype of PTC, and many cases
of CCVPC are aggressive. Encapsulated CCVPC occur in
young or female patients, and extracapsulated CCVPC occur
in older or male patients. CCVPC is described as an
aggressive form of PTC and usually correlates with a poor
prognosis, which may even lead to death [47–49]. However,
encapsulated CCVPC (ECCVPC) is a rare variant of CCVPC
representing between 0.15 and 0.2% of all PTCs [50]. In
general, the CCVPC is characterized by extrathyroidal exten-
sion with cervical metastasis and distant metastases using
diagnostic histopathology. This variant may be identical to
TCVPC with the exception that TCVPC is characterized by
papillae that are delineated by a single layer of tall cells
with an abundant acidophilic cytoplasm and the presence
of granules that give an oncocytic appearance. CCVPC
induces stratiﬁed prominent, clear cytoplasm that is remi-
niscent of subnuclear vacuolated cells, resembling secretory
endometrium [21]. The neoplastic cells are positive for
thyroglobulin and TTF-1. In CCVPC, V600E mutations
in the BRAF gene are detected and may be associated
with increased cyclin D1, Ki-67 proliferation, and nuclear
expression of estrogen and progesterone [51].
9.ClearCellVariant(CLCVPC)
CLCVPC is deﬁned by the World Health Organization
(WHO) [52] as a neoplasm that is predominantly composed
of clear cells and papillary or follicular growth and mainly
aﬀects women between the sixth and seventh decade of life
[53]. Histologically, CLCVPC is characterized by clear cyto-
plasm, which is probably due to TSH overstimulation. The
nuclear features are similar to conventional PTC. Immuno-
histochemicalstudiesrevealthatCLCVPCischaracterizedby
TTF-1, thyroglobulin, HMBE, and Galectin-1 [15].
10. Cribriform-MorularVariant(C-MVPC)
C-MVPC of PTC is a rare morphologic entity. It was ﬁrst
described by Harach et al. [54] in association with familiar
adenomatous polyposis (FAP) as a distinctive tumor. C-
MVPC of PTC is common in young females usually less
than 30 years of age. The lesions are encapsulated or well
circumscribed.AlthoughsporadicformsofC-MVPCusually
appear as isolated tumors, the cases that are associated with
FAP are often multifocal because diﬀerentsomaticmutations
are added to the germline mutations [55, 56]. They display
the characteristic histologic pattern of cribriforming akin to
that seen in breast cancer with morules [57]. This tumor
type is characterized by a prominent cribriform pattern
of growth with interspersed squamoid islands (morules)
that frequently harbor nuclei ﬁlled with lightly eosinophilic,
homogeneous inclusions, closely packed follicles, papillae,
and trabecular. Characteristically, the luminal spaces are
devoidofcolloids.Thetumorcellsarecolumnarorcuboidal,
and the nuclei are often chromatin rich. The nuclear
grooves, pale or clear nuclei, and intranuclear cytoplasmic
inclusionsareoftenobservedfocally.Sometumorcellscanbe
plump and spindle shaped, forming fascicles or whorls. The
neoplasia is often circumscribed or even encapsulated, with
or without capsular and/or vascular invasion [58]. The pres-
ence of squamous morula has been immunohistochemically
analyzed by Hirokawa et al. [59]t od i ﬀerentiate them from
squamous metaplasia, which reveals the following results:
squamous metaplastic cells are immunopositive for low-
and high-molecular-weight cytokeratin and show intense
cell membrane staining for beta-catenin but not Bcl-2.
Conversely, the morular cells are positive with Bcl-2 and
negative or weakly positive for cytokeratin and beta-catenin.
S-100 protein-positive dendritic cells are observed in the
metaplastic nests but not in morules. Finally, Hirokawa et
al. [59] concluded that morules are associated with aberrant
nuclear and cytoplasmic localization of beta-catenin and
are not an early form of squamous metaplasia. In 1994,
Harach et al. [54] ﬁrst characterized thyroid carcinoma
developing in patients with FAP as a distinct follicular cell
tumor in view of its histologic diﬀerences from papillary
and follicular carcinoma. Genetic studies by Cameselle-
Teijeiro et al. [60], have identiﬁed mutations in the BRAF
gene and have demonstrated the association of RET/PTC
and PAX8-PPAR with familial polypoid adenomatosis. The
association of C-MVPC with FAP has been previously
reported. However, Shubadha and Bagwan [61] explained
that the potential absence of polyps during colonoscopy
and germline mutations in the adenomatous polyposis coli
(APC) gene provide evidence that the tumor is a sporadic
counterpart of FAP-associated thyroid carcinoma. C-MVPC
induces a behavior that is similar to conventional PTC,
including the frequent occurrence of cervical metastases.
11.Oncocytic Variant(OCVPC)
Oncocytic thyroid neoplasms are characterized by aberrant
levels of mitochondria. These tumors can occur anywhere
in the thyroid [62]. DeLellis and Williams [52]d e s c r i b e
the OCVPC with mahogany coﬀee-like cells in the papil-
lary or follicular architecture. OCVPC-mediated biological
behavior is variable based on the series reported and the
cases studied. Several studies have not indicated diﬀerences6 ISRN Oncology
betweenOCVPCandconventionalPTC,whereasothershave
suggested that OCVPC is more aggressive than conventional
PTC [63]. OCVPC may be confused with other oncocytic
tumors. The histologic features of the OCVPC include the
proliferation of sheets of large, cohesive cells with abundant
eosinophilic cytoplasm that may be unencapsulated, ill-
deﬁned boundaries, extensive inﬁltration of the surrounding
thyroid parenchyma, follicles with abortive papillae, or
papillary growth. The vast majority of these tumors have
clearnuclei.“OrphanAnnie”nucleihavesomewhatirregular
nuclear membranes with prominent peripheral margination
of chromatin and inconspicuous or absent nucleoli. No
psammoma bodies or areas of calciﬁcation have been
observed. Diﬀerent degrees of stromal ﬁbrosis have been
noted throughout the lesions [64]. The most important
consequence is papillary Hurthle’s cell carcinoma [65]. The
nuclear features of Hurthle’s cell carcinoma diﬀer from those
of oncocytic papillary carcinoma in that the former are char-
acterized by round and vesicular nuclei and prominent cen-
trally placed nucleoli. Focal hyperchromasia, binucleation,
and marked nuclear atypia are common features of these
cells [66]. Other diagnostic considerations in the histological
diﬀerential diagnosis of these tumors include the TCVPC
[66]andtheoncocyticvariantofmedullarycarcinomaofthe
thyroid. In the tall-cell variant of papillary carcinoma, the
cells are also characterized by ample acidophilic cytoplasm.
However, the typical granularity that results from the
packing of mitochondria, which is a hallmark of oncocytic
cells,islacking,andthecytoplasmappearsglassy,probablyas
a consequence of the accumulation of intermediate ﬁlaments
[67]. Berho and Suster [64] have stated that OCVPC is
variable,hasalowgrade,andinducesbehaviorsimilartothat
presented by conventional PTC.
12.FollicularVariant(FVPC)
FVPC is the third most common type of PTC, follow-
ing conventional papillary thyroid carcinoma (CPTC) and
papillary microcarcinoma [68]. Patients with FVPC often
present with a larger tumor size and at a younger age than
patients with CPTC [69]. FVPC also shows less calciﬁcation,
psammoma bodies, and bone formation compared to CPTC.
Furthermore, FVPC has more favorable clinicopathological
featuresandalowertumorriskgroupproﬁlethanCPTC.On
the other hand, the long-term outcome of FVPC patients is
similar to that of CPTC patients [70]. Fine-needle aspiration
(FNA) and frozen sectioning (FS) are techniques that are
routinely used to evaluate thyroid nodules. In the case of
classic PTC, distinct nuclear features have been described
that make deﬁnitive diagnosis with FNA possible [71]. In
cases of FVPC, intraoperative FS and cytologic study are
usedtoidentifythespeciﬁcnuclearcharacteristicsthatdeﬁne
PTC. This feature is distinct from FS of follicular neoplasms,
which indicates that the follicular architecture is identical
in adenomas and carcinomas. Because the nuclear features
may be obscured by freezing artifacts in FS, intraoperative
cytologic study is currently recommended when a diagnosis
of FVPC is in question [72]. Kesmodel et al. [73] have shown
that treatment with total thyroidectomy is not necessary
in all patients, thereby decreasing the number of complete
thyroidectomies. However, there are several arguments to
support total thyroidectomy in this group of patients.
Studies have shown that recurrence rates are lower after
t o t a lt h y r o i d e c t o m yb e c a u s eP T Cm a yb ec h a r a c t e r i z e da sa
multinodular and bilobar disease [74]. However, the disease
may not be adequately managed by thyroid lobectomy alone.
In addition, total thyroidectomy facilitates the use of post-
operative radioiodine to ablate residual disease and enables
endocrinologists to monitor patients for recurrence based
on thyroglobulin levels [74]. FVPC has created continuous
diagnostic controversy among pathologists. FVPC is the
most diﬃcult to diﬀerentiate from other benign thyroid
and malignant thyroid lesions clinically and pathologically.
The concordance rate for the diagnosis of FVPC between
endocrine pathologists is less than 40% [75]. It is likely
that the recent increase in the incidence of thyroid cancer is
related to the mislabeling of some cases of the benign mimics
o fP T Ca sF V P C[ 76]. BRAF is a serine/threonine kinase and
a member of a family of RAF genes that are an integral part
of one of the major pathways controlling cellular growth and
diﬀerentiation. BRAF is a commonly studied gene in thyroid
cancer in recent years. BRAF functions primarily as a signal
transducer between other proteins and the MAPK/ERK
kinase (MEK) via phosphorylation of the BRAF gene [77].
13. Conclusions
PTC is a common malignant neoplasm with excellent
clinicalbehavior,despitethepresenceofcervicallymphnode
metastases; however, there are histologic variants, which can
modifythecourseoftheseneoplasms.Therefore,weconsider
in this paper these variants of particular importance in
histopathological diagnosis because of biological behavior
and clinical characteristics of each of these variants.
The purpose of this study was reviewing the diﬀerent
variants of PTC with diﬀerent histopathological patterns
compared with those with classical PTC. Diﬀerent variants
or histological patterns may coexist in the a same tumor.
The presence of an aggressive variant of papillary car-
cinoma should alert the surgeon that he is dealing with
a potentially aggressive tumor. Clinical treatment decisions
should be based on the stage of the disease, inﬂuenced by the
knowledge that the aggressive variants tend to be associated
with higher risk factors [20].
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